Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Hafiza Padinharayil; Jinsu Varghese; Mithun Chacko John; Golgodu Krishnamurthy Rajanikant; Cornelia M. Wilson; Minnatallah Al-Yozbaki; Kaviyarasi Renu; Saikat Dewanjee; Rupa Sanyal; Abhijit Dey; Anirban Goutam Mukherjee; Uddesh Ramesh Wanjari; Abilash Valsala Gopalakrishnan; Alex George

doi:10.1016/j.gendis.2022.07.023

您当前的位置：

首页 >

文章列表页 >

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Review article | 更新时间：2023-08-29

- Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
- Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
- Genes & Diseases 2023年10卷第3期
- 作者机构：
  
  1. Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu,India,632014
  2. Canterbury Christ Church University, Natural Applied Sciences, Life Sciences Industry Liaison Lab, Discovery Park, Sandwich CT13 9FF, United Kingdom
  3. Department of Life Sciences, Presidency University, Kolkata, West Bengal,India,700073
  4. Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal,India,700032
  5. Department of Medical Oncology, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala,India,680005
  6. Jubilee Centre for Medical Research, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala,India,680005
  7. School of Biotechnology, National Institute of Technology, Calicut, Kerala,India,673601
  8. Centre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College & Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University,, Tamil Nadu,Chennai,India,600077
  9. PG & Research Department of Zoology, St. Thomas College, Kozhenchery, Pathanamthitta, Kerala,India,689641
  10. Department of Botany, Bhairab Ganguly College, Feeder Road, Belghoria, Kolkata, West Bengal,India,700056
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.07.023
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-5-1，
扫描看全文
Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, 等. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics[J]. Genes & Diseases, 2023,10(3).

Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics[J]. Genes & Diseases, 2023,10(3).
Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, 等. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics[J]. Genes & Diseases, 2023,10(3). DOI： 10.1016/j.gendis.2022.07.023.

Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics[J]. Genes & Diseases, 2023,10(3). DOI： 10.1016/j.gendis.2022.07.023.

摘要

Abstract

Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention

diagnosis

and management

supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030

surpassing non-small cell lung cancer (NSCLC)

which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC

the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies

followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs)

circulating cell-free tumor DNA (cfDNA)

tumor educated platelets (TEP)

and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer

acquired resistance caused by various generations of therapeutic agents

refractory disease

prognosis

and surveillance.

关键词

Keywords

BiomarkerClinical trialEpidemiologyHistologyLiquid biopsyNSCLCTargeted therapy

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Advances in the early diagnosis of hepatocellular carcinoma

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

Vitamin D-binding protein in plasma microglia-derived extracellular vesicles as a potential biomarker for major depressive disorder